In a meta-analysis 6 of eight trials with 60080 patients (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6, and AMPLITUDE-O) , treatment with a GLP-1 receptor agonist led to a 14% relative risk reduction in three-point MACE (HR 086 [95% CI 080093]
Also, glutathione helps to restore tissues by building blocks of the proteins
Know what you are dealing with before choosing a treatment approach
Clinical trials have demonstrated that certain GLP-1 receptor agonists can: These benefits have changed how clinicians approach diabetes management, particularly for patients at high cardiovascular or renal risk
We found that after eight weeks of TAC, the levels of cardiac glycolysis-related metabolites (glucose 6-P, fructose 6-P, 3-PG, PEP, and pyruvate), the pentose phosphate pathway (PPP) (glucose-1-P, 6-PG, and ribose-5-P) and lipids (stearic acid et al) were significantly increased, but the amount of pyruvate entering the TCA cycle (citrate and aconitate) was reduced (Fig
Tymlos: A new force in the osteoporosis market Conclusion: In postmenopausal osteoporosis patients at high risk of fracture, Tymlos offers improved efficacy at a much lower price than Forteo
